# KEYNOTE-689 (NCT03765918)

> Study of Pembrolizumab Given Prior to Surgery and in Combination With Radiotherapy Given Post-surgery for Advanced Head and Neck Squamous Cell Carcinoma (MK-3475-689)

No report yet. It can be ordered.

## Registry

- Registry record: https://clinicaltrials.gov/study/NCT03765918
- Phase: PHASE3
- Status: ACTIVE_NOT_RECRUITING
- Sponsor: Merck Sharp & Dohme LLC
- Conditions: Head and Neck Neoplasms
- Interventions: Pembrolizumab 200 mg; Radiotherapy 60 Gray; Radiotherapy 66 Gray; Radiotherapy 70 Gray; Cisplatin 100 mg/m^2
- Enrollment: 714
- Primary outcome: Event-free Survival (EFS)
- Primary outcome: EFS in Participants With Programmed Cell Death Ligand 1 (PD-L1) Combined Positive Score (CPS) ≥10
- Primary outcome: EFS in Participants With PD-L1 CPS ≥1

## Indexed commentary on KEYNOTE-689 so far

Podcasts, YouTube videos and X posts we have indexed that name the trial. This is where a report starts, not where it ends: the build searches for more, so finished reports usually cover more than this.

- X threads: 53
- YouTube: 42
- Podcasts: 29
- Bluesky threads: 2
- X videos: 1

## Order

Deep, $1,950, price fixed at order: https://www.erudio.com/contact?report=keynote-689-nct03765918

## Free preview

POST https://www.erudio.com/api/trial-requests with {"nct_id": "NCT03765918", "email": "<work email>"}; the inbox owner confirms by the emailed link.